Sign In

Login

Password

Forgot Password ? Sign Up

Bupropion (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bupropion" in Polish language version.

refsWebsite
Global rank Polish rank
58nih.gov
4th place
7th place
52doi.org
2nd place
6th place
12web.archive.org
1st place
1st place
5fda.gov
447th place
1,118th place
3gsk.com
low place
9,153rd place
2psychiatrist.com
low place
low place
2archive.org
6th place
33rd place
2archive.is
87th place
5th place
2tga.gov.au
3,984th place
low place
1doz.pl
low place
1,765th place
1sigmaaldrich.com
924th place
75th place
1mp.pl
8,738th place
165th place
1worldcat.org
5th place
2nd place
1quackwatch.org
low place
7,248th place
1medicines.org.uk
3,823rd place
low place
1mhra.gov.uk
low place
low place
1aspetjournals.org
6,663rd place
7,639th place
1biospace.com
low place
low place
1uspto.gov
1,459th place
3,191st place
1emedexpert.com
low place
low place
1drugabuse.gov
6,166th place
low place
1cnn.com
28th place
76th place
1medscape.com
719th place
1,030th place
1webcitation.org
24th place
107th place
1peoplespharmacy.com
low place
low place
1msn.com
117th place
278th place
1gazeta.pl
1,879th place
30th place
1nytimes.com
7th place
29th place
1afssaps.fr
low place
low place
1docguide.com
low place
low place

afssaps.fr

archive.is

  • FDA clears Cymbalta to treat chronic musculoskeletal pain. [w:] FDA Press Announcements [on-line]. Food and Drug Administration, 2010-11-04. [dostęp 2013-08-19]. Cytat: The U.S. Food and Drug Administration ... approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.
  • Bupropion. Stahlonline.cambridge.org: Cambridge University Press. [dostęp 2010-04-27].

archive.org

aspetjournals.org

jpet.aspetjournals.org

biospace.com

cnn.com

docguide.com

doi.org

dx.doi.org

  • Daniel M. Perrine i inni, A Short, One-Pot Synthesis of Bupropion (Zyban, Wellbutrin), „Journal of Chemical Education”, 77 (11), 2000, s. 1479, DOI: 10.1021/ed077p1479 [dostęp 2022-10-24] (ang.).
  • Giovanni W. Amarante, Mayra Cavallaro, Fernando Coelho, Hyphenating the curtius rearrangement with Morita-Baylis-Hillman adducts: synthesis of biologically active acyloins and vicinal aminoalcohols, „Journal of the Brazilian Chemical Society”, 22 (8), 2011, s. 1568–1584, DOI: 10.1590/S0103-50532011000800022 [dostęp 2022-10-24] (ang.).
  • Charles W. Schindler i inni, Comparison of the effects of methamphetamine, bupropion and methylphenidate on the self-administration of methamphetamine by rhesus monkeys, „Experimental and Clinical Psychopharmacology”, 19 (1), 2011, s. 1–10, DOI: 10.1037/a0022432, PMID: 21341918, PMCID: PMC3392967.
  • R. Moreira, The efficacy and tolerability of bupropion in the treatment of major depressive disorder, „Clin Drug Investig”, 31, 2011, s. 5–17, DOI: 10.2165/1159616-S0-000000000-00000, PMID: 22015858 (ang.).
  • Andrea Cipriani i inni, Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis, „The Lancet”, 373 (9665), 2009, s. 746–758, DOI: 10.1016/S0140-6736(09)60046-5, PMID: 19185342 [dostęp 2022-10-24] (ang.).
  • Agnes Higgins, Antidepressant-associated sexual dysfunction: impact, effects, and treatment, „Drug, Healthcare and Patient Safety”, 2010, s. 141, DOI: 10.2147/DHPS.S7634, PMID: 21701626, PMCID: PMC3108697 [dostęp 2022-10-24] (ang.).
  • Sohita Dhillon, Lily P.H. Yang, Monique P. Curran, Bupropion: a review of its use in the management of major depressive disorder, „Drugs”, 68 (5), 2008, s. 653–689, DOI: 10.2165/00003495-200868050-00011, PMID: 18370448 [dostęp 2022-10-24] (ang.).
  • George I. Papakostas i inni, Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies, „The Journal of Clinical Psychiatry”, 69 (8), 2008, s. 1287–1292, DOI: 10.4088/jcp.v69n0812, PMID: 18605812 [dostęp 2022-10-24] (ang.).
  • Ping Wu i inni, Effectiveness of smoking cessation therapies: a systematic review and meta-analysis, „BMC Public Health”, 6 (1), 2006, s. 300, DOI: 10.1186/1471-2458-6-300, PMID: 17156479, PMCID: PMC1764891 [dostęp 2022-10-24] (ang.).
  • Rachel Kornfield i inni, Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004–2008, „Psychiatric Services”, 64 (4), 2013, s. 339–346, DOI: 10.1176/appi.ps.201200147, PMID: 23318985, PMCID: PMC4023684 [dostęp 2022-10-24] (ang.).
  • Steven Pliszka, AACAP Work Group on Quality Issues, Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder, „Journal of the American Academy of Child and Adolescent Psychiatry”, 46 (7), 2007, s. 894–921, DOI: 10.1097/chi.0b013e318054e724, PMID: 17581453 [dostęp 2022-10-24] (ang.).
  • Steven R. Pliszka i inni, The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder, „Journal of the American Academy of Child and Adolescent Psychiatry”, 45 (6), 2006, s. 642–657, DOI: 10.1097/01.chi.0000215326.51175.eb, PMID: 16721314 [dostęp 2022-10-24] (ang.).
  • Alessandro Serretti, Alberto Chiesa, Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis, „Journal of Clinical Psychopharmacology”, 29 (3), 2009, s. 259–266, DOI: 10.1097/JCP.0b013e3181a5233f, PMID: 19440080 [dostęp 2022-10-24] (ang.).
  • Stephen M. Stahl i inni, A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor, „The Primary Care Companion to The Journal of Clinical Psychiatry”, 06 (04), 2004, s. 159–166, DOI: 10.4088/PCC.v06n0403, PMID: 15361919, PMCID: PMC514842 [dostęp 2022-10-24].
  • Kevin F. Foley, Kevin P. DeSanty, Richard E. Kast, Bupropion: pharmacology and therapeutic applications, „Expert Review of Neurotherapeutics”, 6 (9), 2006, s. 1249–1265, DOI: 10.1586/14737175.6.9.1249, PMID: 17009913 [dostęp 2022-10-24] (ang.).
  • Zhaoping Li i inni, Meta-analysis: pharmacologic treatment of obesity, „Annals of Internal Medicine”, 142 (7), 2005, s. 532–546, DOI: 10.7326/0003-4819-142-7-200504050-00012, PMID: 15809465 [dostęp 2022-10-24] (ang.).
  • Donna H. Ryan, George A. Bray, Pharmacologic treatment options for obesity: what is old is new again, „Current Hypertension Reports”, 15 (3), 2013, s. 182–189, DOI: 10.1007/s11906-013-0343-6, PMID: 23625271 [dostęp 2022-10-24] (ang.).
  • Harm J. Gijsman i inni, Antidepressants for bipolar depression: a systematic review of randomized, controlled trials, „The American Journal of Psychiatry”, 161 (9), 2004, s. 1537–1547, DOI: 10.1176/appi.ajp.161.9.1537, PMID: 15337640 [dostęp 2022-10-24] (ang.).
  • Lakshmi N. Yatham i inni, Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007, „Bipolar Disorders”, 8 (6), 2006, s. 721–739, DOI: 10.1111/j.1399-5618.2006.00432.x, PMID: 17156158 [dostęp 2022-10-24] (ang.).
  • Kyle Kampman, The Search for Medications to Treat Stimulant Dependence, „Addiction Science & Clinical Practice”, 4 (2), 2008, s. 28–35, DOI: 10.1151/ascp084228, PMID: 18497715, PMCID: PMC2797110 [dostęp 2022-10-24] (ang.).
  • Antonina A Mikocka-Walus i inni, Antidepressants and inflammatory bowel disease: a systematic review, „Clinical Practice and Epidemiology in Mental Health”, 2 (1), 2006, s. 24, DOI: 10.1186/1745-0179-2-24 [dostęp 2022-10-24] (ang.).
  • D.M. Urquhart i inni, Antidepressants for non-specific low back pain, „Cochrane Database of Systematic Reviews” (1), 2008, CD001703, DOI: 10.1002/14651858.CD001703.pub3, PMID: 18253994, PMCID: PMC7025781 [dostęp 2022-10-24] (ang.).
  • Tanmay H. Shah, Abdolali Moradimehr, Bupropion for the treatment of neuropathic pain, „The American Journal of Hospice & Palliative Care”, 27 (5), 2010, s. 333–336, DOI: 10.1177/1049909110361229, PMID: 20185402 [dostęp 2022-10-24] (ang.).
  • Francesco Pisani i inni, Effects of psychotropic drugs on seizure threshold, „Drug Safety”, 25 (2), 2002, s. 91–110, DOI: 10.2165/00002018-200225020-00004, PMID: 11888352 (ang.).
  • Kenneth Alper i inni, Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports, „Biological Psychiatry”, 62 (4), 2007, s. 345–354, DOI: 10.1016/j.biopsych.2006.09.023, PMID: 17223086 (ang.).
  • D. Taylor, Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety, „Acta Psychiatrica Scandinavica”, 118 (6), 2008, s. 434–442, DOI: 10.1111/j.1600-0447.2008.01260.x, PMID: 18785947 (ang.).
  • R. Hubbard i inni, Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network, „Thorax”, 60 (10), 2005, s. 848–850, DOI: 10.1136/thx.2005.041798, PMID: 16055620, PMCID: PMC1747199.
  • J.R. Hughes, L.F. Stead, T. Lancaster, Antidepressants for smoking cessation, „The Cochrane Database of Systematic Reviews” (1), 2007, art. nr CD000031, DOI: 10.1002/14651858.CD000031.pub3, PMID: 17253443 (ang.).
  • Seth Howes i inni, Antidepressants for smoking cessation, „Cochrane Database of Systematic Reviews”, 2021 (5), 2020, DOI: 10.1002/14651858.CD000031.pub5, PMID: 32319681, PMCID: PMC7175455 [dostęp 2022-10-24] (ang.).
  • Sanjeev Kumar i inni, Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature, „General Hospital Psychiatry”, 33 (6), 2011, s. 612–617, DOI: 10.1016/j.genhosppsych.2011.07.001, PMID: 21872337 (ang.).
  • W.T. Howard, J.K. Warnock, Bupropion-induced psychosis, „The American Journal of Psychiatry”, 156 (12), 1999, s. 2017–2018, DOI: 10.1176/ajp.156.12.2017-a, PMID: 10588428 (ang.).
  • T. Javelot i inni, Troubles psychotiques aigus liés au bupropion: revue de la littérature, „L’Encephale”, 36 (6), 2010, s. 461–471, DOI: 10.1016/j.encep.2010.01.005, PMID: 21130229 (fr.).
  • Timothy R. Berigan, Bupropion-Associated Withdrawal Symptoms Revisited: A Case Report, „Primary Care Companion to the Journal of Clinical Psychiatry”, 4 (2), 2002, s. 78–79, DOI: 10.4088/PCC.v04n0208a, PMID: 15014751, PMCID: PMC181231.
  • James W. Jefferson, James F. Pradko, Keith T. Muir, Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations, „Clinical Therapeutics”, 27 (11), 2005, s. 1685–1695, DOI: 10.1016/j.clinthera.2005.11.011, PMID: 16368442 (ang.).
  • Linda P. Dwoskin i inni, Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent, „CNS drug reviews”, 12 (3-4), 2006, s. 178–207, DOI: 10.1111/j.1527-3458.2006.00178.x, PMID: 17227286, PMCID: PMC6506196 [dostęp 2022-10-24] (ang.).
  • Nicole White, Toby Litovitz, Cathleen Clancy, Suicidal antidepressant overdoses: a comparative analysis by antidepressant type, „Journal of Medical Toxicology”, 4 (4), 2008, s. 238–250, DOI: 10.1007/BF03161207, PMID: 19031375, PMCID: PMC3550116.
  • Michael C. Beuhler, Henry A. Spiller, Howell C. Sasser, The outcome of unintentional pediatric bupropion ingestions: a NPDS database review, „Journal of Medical Toxicology”, 6 (1), 2010, s. 4–8, DOI: 10.1007/s13181-010-0027-4, PMID: 20213217, PMCID: PMC3550434.
  • Henry A. Spiller, Edward Bottei, Linda Kalin, Fatal bupropion overdose with post mortem blood concentrations, „Forensic Science, Medicine, and Pathology”, 4 (1), 2008, s. 47–50, DOI: 10.1007/s12024-007-0030-5, PMID: 19291469.
  • Jeffrey H. Meyer i inni, Bupropion occupancy of the dopamine transporter is low during clinical treatment, „Psychopharmacology”, 163 (1), 2002, s. 102–105, DOI: 10.1007/s00213-002-1166-3, PMID: 12185406 [dostęp 2022-10-24] (ang.).
  • Susan M. Learned-Coughlin i inni, In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography, „Biological Psychiatry”, 54 (8), 2003, s. 800–805, DOI: 10.1016/s0006-3223(02)01834-6, PMID: 14550679 [dostęp 2022-10-24] (ang.).
  • Hugo R. Arias, Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?, „The International Journal of Biochemistry & Cell Biology”, 41 (11), 2009, s. 2098–2108, DOI: 10.1016/j.biocel.2009.05.015, PMID: 19497387 [dostęp 2022-10-24] (ang.).
  • W.D. Horst, S.H. Preskorn, Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion, „Journal of Affective Disorders”, 51 (3), 1998, s. 237–254, DOI: 10.1016/s0165-0327(98)00222-5, PMID: 10333980 [dostęp 2022-10-24] (ang.).
  • Andrew J. Johnston i inni, Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation, „Drugs”, 62 Suppl 2, 2002, s. 11–24, DOI: 10.2165/00003495-200262002-00002, PMID: 12109932 [dostęp 2022-10-24] (ang.).
  • Hongmei Xu i inni, Stereoselective analysis of hydroxybupropion and application to drug interaction studies, „Chirality”, 19 (3), 2007, s. 163–170, DOI: 10.1002/chir.20356, PMID: 17167747 [dostęp 2022-10-24] (ang.).
  • Mikhail L. Bondarev i inni, Behavioral and biochemical investigations of bupropion metabolites, „European Journal of Pharmacology”, 474 (1), 2003, s. 85–93, DOI: 10.1016/s0014-2999(03)02010-7, PMID: 12909199 [dostęp 2022-10-24] (ang.).
  • M. Imad Damaj i inni, Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors, „Molecular Pharmacology”, 66 (3), 2004, s. 675–682, DOI: 10.1124/mol.104.001313, PMID: 15322260 [dostęp 2022-10-24] (ang.).
  • Arne Meyer i inni, Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 41 (9), 2013, s. 1671–1678, DOI: 10.1124/dmd.113.052936, PMID: 23804523, PMCID: PMC3876805 [dostęp 2022-10-24] (ang.).
  • Leah M. Hesse i inni, Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes, „Pharmacogenetics”, 14 (4), 2004, s. 225–238, DOI: 10.1097/00008571-200404000-00002, PMID: 15083067 [dostęp 2022-10-24] (ang.).
  • R.M. Welch, A.A. Lai, D.H. Schroeder, Pharmacological significance of the species differences in bupropion metabolism, „Xenobiotica; the Fate of Foreign Compounds in Biological Systems”, 17 (3), 1987, s. 287–298, DOI: 10.3109/00498258709043939, PMID: 3107223 [dostęp 2022-10-24] (ang.).
  • D. Weintraub, M.W. Linder, Amphetamine positive toxicology screen secondary to bupropion, „Depression and Anxiety”, 12 (1), 2000, s. 53–54, DOI: 10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4, PMID: 10999247 [dostęp 2022-10-24] (ang.).
  • A.L. Nixon i inni, Bupropion metabolites produce false-positive urine amphetamine results, „Clinical Chemistry”, 41 (6 Pt 1), 1995, s. 955–956, DOI: 10.1093/clinchem/41.6.955, PMID: 7768026 [dostęp 2022-10-24] (ang.).
  • Joshua A. Lile, Michael A. Nader, The Abuse Liability and Therapeutic Potential of Drugs Evaluated for Cocaine Addiction as Predicted by Animal Models, „Current Neuropharmacology”, 1 (1), s. 21–46, DOI: 10.2174/1570159033360566 [dostęp 2022-10-24] (ang.).

doz.pl

  • Chlorowodorek bupropionu, [w:] Encyklopedia leków i suplementów – lekopedia [online], www.doz.pl [dostęp 2016-12-02].

drugabuse.gov

emedexpert.com

fda.gov

fda.gov

accessdata.fda.gov

gazeta.pl

wiadomosci.gazeta.pl

gsk.com

us.gsk.com

gsk.com

medicines.org.uk

medscape.com

mhra.gov.uk

mp.pl

msn.com

msnbc.msn.com

nih.gov

ncbi.nlm.nih.gov

  • Charles W. Schindler i inni, Comparison of the effects of methamphetamine, bupropion and methylphenidate on the self-administration of methamphetamine by rhesus monkeys, „Experimental and Clinical Psychopharmacology”, 19 (1), 2011, s. 1–10, DOI: 10.1037/a0022432, PMID: 21341918, PMCID: PMC3392967.
  • R. Moreira, The efficacy and tolerability of bupropion in the treatment of major depressive disorder, „Clin Drug Investig”, 31, 2011, s. 5–17, DOI: 10.2165/1159616-S0-000000000-00000, PMID: 22015858 (ang.).
  • Andrea Cipriani i inni, Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis, „The Lancet”, 373 (9665), 2009, s. 746–758, DOI: 10.1016/S0140-6736(09)60046-5, PMID: 19185342 [dostęp 2022-10-24] (ang.).
  • Agnes Higgins, Antidepressant-associated sexual dysfunction: impact, effects, and treatment, „Drug, Healthcare and Patient Safety”, 2010, s. 141, DOI: 10.2147/DHPS.S7634, PMID: 21701626, PMCID: PMC3108697 [dostęp 2022-10-24] (ang.).
  • Sohita Dhillon, Lily P.H. Yang, Monique P. Curran, Bupropion: a review of its use in the management of major depressive disorder, „Drugs”, 68 (5), 2008, s. 653–689, DOI: 10.2165/00003495-200868050-00011, PMID: 18370448 [dostęp 2022-10-24] (ang.).
  • David S. Baldwin, George I. Papakostas, Symptoms of fatigue and sleepiness in major depressive disorder, „The Journal of Clinical Psychiatry”, 67 (suppl. 6), 2006, s. 9–15, PMID: 16848671 [dostęp 2022-10-24] (ang.).
  • George I. Papakostas i inni, Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies, „The Journal of Clinical Psychiatry”, 69 (8), 2008, s. 1287–1292, DOI: 10.4088/jcp.v69n0812, PMID: 18605812 [dostęp 2022-10-24] (ang.).
  • Ping Wu i inni, Effectiveness of smoking cessation therapies: a systematic review and meta-analysis, „BMC Public Health”, 6 (1), 2006, s. 300, DOI: 10.1186/1471-2458-6-300, PMID: 17156479, PMCID: PMC1764891 [dostęp 2022-10-24] (ang.).
  • First drug for seasonal depression, „FDA consumer”, 40 (5), 2006, s. 7, PMID: 17328102 [dostęp 2022-10-24] (ang.).
  • Rachel Kornfield i inni, Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004–2008, „Psychiatric Services”, 64 (4), 2013, s. 339–346, DOI: 10.1176/appi.ps.201200147, PMID: 23318985, PMCID: PMC4023684 [dostęp 2022-10-24] (ang.).
  • D.P. Cantwell, ADHD through the life span: the role of bupropion in treatment, „The Journal of Clinical Psychiatry”, 59 (suppl. 4), 1998, s. 92–94, PMID: 9554326 [dostęp 2022-10-24] (ang.).
  • Steven Pliszka, AACAP Work Group on Quality Issues, Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder, „Journal of the American Academy of Child and Adolescent Psychiatry”, 46 (7), 2007, s. 894–921, DOI: 10.1097/chi.0b013e318054e724, PMID: 17581453 [dostęp 2022-10-24] (ang.).
  • Steven R. Pliszka i inni, The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder, „Journal of the American Academy of Child and Adolescent Psychiatry”, 45 (6), 2006, s. 642–657, DOI: 10.1097/01.chi.0000215326.51175.eb, PMID: 16721314 [dostęp 2022-10-24] (ang.).
  • Alessandro Serretti, Alberto Chiesa, Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis, „Journal of Clinical Psychopharmacology”, 29 (3), 2009, s. 259–266, DOI: 10.1097/JCP.0b013e3181a5233f, PMID: 19440080 [dostęp 2022-10-24] (ang.).
  • Stephen M. Stahl i inni, A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor, „The Primary Care Companion to The Journal of Clinical Psychiatry”, 06 (04), 2004, s. 159–166, DOI: 10.4088/PCC.v06n0403, PMID: 15361919, PMCID: PMC514842 [dostęp 2022-10-24].
  • Kevin F. Foley, Kevin P. DeSanty, Richard E. Kast, Bupropion: pharmacology and therapeutic applications, „Expert Review of Neurotherapeutics”, 6 (9), 2006, s. 1249–1265, DOI: 10.1586/14737175.6.9.1249, PMID: 17009913 [dostęp 2022-10-24] (ang.).
  • Zhaoping Li i inni, Meta-analysis: pharmacologic treatment of obesity, „Annals of Internal Medicine”, 142 (7), 2005, s. 532–546, DOI: 10.7326/0003-4819-142-7-200504050-00012, PMID: 15809465 [dostęp 2022-10-24] (ang.).
  • Donna H. Ryan, George A. Bray, Pharmacologic treatment options for obesity: what is old is new again, „Current Hypertension Reports”, 15 (3), 2013, s. 182–189, DOI: 10.1007/s11906-013-0343-6, PMID: 23625271 [dostęp 2022-10-24] (ang.).
  • Harm J. Gijsman i inni, Antidepressants for bipolar depression: a systematic review of randomized, controlled trials, „The American Journal of Psychiatry”, 161 (9), 2004, s. 1537–1547, DOI: 10.1176/appi.ajp.161.9.1537, PMID: 15337640 [dostęp 2022-10-24] (ang.).
  • Lakshmi N. Yatham i inni, Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007, „Bipolar Disorders”, 8 (6), 2006, s. 721–739, DOI: 10.1111/j.1399-5618.2006.00432.x, PMID: 17156158 [dostęp 2022-10-24] (ang.).
  • Kyle Kampman, The Search for Medications to Treat Stimulant Dependence, „Addiction Science & Clinical Practice”, 4 (2), 2008, s. 28–35, DOI: 10.1151/ascp084228, PMID: 18497715, PMCID: PMC2797110 [dostęp 2022-10-24] (ang.).
  • D.M. Urquhart i inni, Antidepressants for non-specific low back pain, „Cochrane Database of Systematic Reviews” (1), 2008, CD001703, DOI: 10.1002/14651858.CD001703.pub3, PMID: 18253994, PMCID: PMC7025781 [dostęp 2022-10-24] (ang.).
  • Tanmay H. Shah, Abdolali Moradimehr, Bupropion for the treatment of neuropathic pain, „The American Journal of Hospice & Palliative Care”, 27 (5), 2010, s. 333–336, DOI: 10.1177/1049909110361229, PMID: 20185402 [dostęp 2022-10-24] (ang.).
  • Francesco Pisani i inni, Effects of psychotropic drugs on seizure threshold, „Drug Safety”, 25 (2), 2002, s. 91–110, DOI: 10.2165/00002018-200225020-00004, PMID: 11888352 (ang.).
  • Kenneth Alper i inni, Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports, „Biological Psychiatry”, 62 (4), 2007, s. 345–354, DOI: 10.1016/j.biopsych.2006.09.023, PMID: 17223086 (ang.).
  • D. Taylor, Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety, „Acta Psychiatrica Scandinavica”, 118 (6), 2008, s. 434–442, DOI: 10.1111/j.1600-0447.2008.01260.x, PMID: 18785947 (ang.).
  • R. Hubbard i inni, Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network, „Thorax”, 60 (10), 2005, s. 848–850, DOI: 10.1136/thx.2005.041798, PMID: 16055620, PMCID: PMC1747199.
  • J.R. Hughes, L.F. Stead, T. Lancaster, Antidepressants for smoking cessation, „The Cochrane Database of Systematic Reviews” (1), 2007, art. nr CD000031, DOI: 10.1002/14651858.CD000031.pub3, PMID: 17253443 (ang.).
  • Seth Howes i inni, Antidepressants for smoking cessation, „Cochrane Database of Systematic Reviews”, 2021 (5), 2020, DOI: 10.1002/14651858.CD000031.pub5, PMID: 32319681, PMCID: PMC7175455 [dostęp 2022-10-24] (ang.).
  • Sanjeev Kumar i inni, Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature, „General Hospital Psychiatry”, 33 (6), 2011, s. 612–617, DOI: 10.1016/j.genhosppsych.2011.07.001, PMID: 21872337 (ang.).
  • W.T. Howard, J.K. Warnock, Bupropion-induced psychosis, „The American Journal of Psychiatry”, 156 (12), 1999, s. 2017–2018, DOI: 10.1176/ajp.156.12.2017-a, PMID: 10588428 (ang.).
  • T. Javelot i inni, Troubles psychotiques aigus liés au bupropion: revue de la littérature, „L’Encephale”, 36 (6), 2010, s. 461–471, DOI: 10.1016/j.encep.2010.01.005, PMID: 21130229 (fr.).
  • Timothy R. Berigan, Bupropion-Associated Withdrawal Symptoms Revisited: A Case Report, „Primary Care Companion to the Journal of Clinical Psychiatry”, 4 (2), 2002, s. 78–79, DOI: 10.4088/PCC.v04n0208a, PMID: 15014751, PMCID: PMC181231.
  • James W. Jefferson, James F. Pradko, Keith T. Muir, Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations, „Clinical Therapeutics”, 27 (11), 2005, s. 1685–1695, DOI: 10.1016/j.clinthera.2005.11.011, PMID: 16368442 (ang.).
  • Linda P. Dwoskin i inni, Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent, „CNS drug reviews”, 12 (3-4), 2006, s. 178–207, DOI: 10.1111/j.1527-3458.2006.00178.x, PMID: 17227286, PMCID: PMC6506196 [dostęp 2022-10-24] (ang.).
  • Nicole White, Toby Litovitz, Cathleen Clancy, Suicidal antidepressant overdoses: a comparative analysis by antidepressant type, „Journal of Medical Toxicology”, 4 (4), 2008, s. 238–250, DOI: 10.1007/BF03161207, PMID: 19031375, PMCID: PMC3550116.
  • Michael C. Beuhler, Henry A. Spiller, Howell C. Sasser, The outcome of unintentional pediatric bupropion ingestions: a NPDS database review, „Journal of Medical Toxicology”, 6 (1), 2010, s. 4–8, DOI: 10.1007/s13181-010-0027-4, PMID: 20213217, PMCID: PMC3550434.
  • J.A. Johnston i inni, A 102-center prospective study of seizure in association with bupropion, „The Journal of Clinical Psychiatry”, 52 (11), 1991, s. 450–456, PMID: 1744061 (ang.).
  • Henry A. Spiller, Edward Bottei, Linda Kalin, Fatal bupropion overdose with post mortem blood concentrations, „Forensic Science, Medicine, and Pathology”, 4 (1), 2008, s. 47–50, DOI: 10.1007/s12024-007-0030-5, PMID: 19291469.
  • Jeffrey H. Meyer i inni, Bupropion occupancy of the dopamine transporter is low during clinical treatment, „Psychopharmacology”, 163 (1), 2002, s. 102–105, DOI: 10.1007/s00213-002-1166-3, PMID: 12185406 [dostęp 2022-10-24] (ang.).
  • Susan M. Learned-Coughlin i inni, In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography, „Biological Psychiatry”, 54 (8), 2003, s. 800–805, DOI: 10.1016/s0006-3223(02)01834-6, PMID: 14550679 [dostęp 2022-10-24] (ang.).
  • L.L. Howell, K.M. Wilcox, The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates, „The Journal of Pharmacology and Experimental Therapeutics”, 298 (1), 2001, s. 1–6, PMID: 11408518 [dostęp 2022-10-24] (ang.).
  • Hugo R. Arias, Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?, „The International Journal of Biochemistry & Cell Biology”, 41 (11), 2009, s. 2098–2108, DOI: 10.1016/j.biocel.2009.05.015, PMID: 19497387 [dostęp 2022-10-24] (ang.).
  • W.D. Horst, S.H. Preskorn, Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion, „Journal of Affective Disorders”, 51 (3), 1998, s. 237–254, DOI: 10.1016/s0165-0327(98)00222-5, PMID: 10333980 [dostęp 2022-10-24] (ang.).
  • Andrew J. Johnston i inni, Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation, „Drugs”, 62 Suppl 2, 2002, s. 11–24, DOI: 10.2165/00003495-200262002-00002, PMID: 12109932 [dostęp 2022-10-24] (ang.).
  • Hongmei Xu i inni, Stereoselective analysis of hydroxybupropion and application to drug interaction studies, „Chirality”, 19 (3), 2007, s. 163–170, DOI: 10.1002/chir.20356, PMID: 17167747 [dostęp 2022-10-24] (ang.).
  • Mikhail L. Bondarev i inni, Behavioral and biochemical investigations of bupropion metabolites, „European Journal of Pharmacology”, 474 (1), 2003, s. 85–93, DOI: 10.1016/s0014-2999(03)02010-7, PMID: 12909199 [dostęp 2022-10-24] (ang.).
  • M. Imad Damaj i inni, Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors, „Molecular Pharmacology”, 66 (3), 2004, s. 675–682, DOI: 10.1124/mol.104.001313, PMID: 15322260 [dostęp 2022-10-24] (ang.).
  • Arne Meyer i inni, Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 41 (9), 2013, s. 1671–1678, DOI: 10.1124/dmd.113.052936, PMID: 23804523, PMCID: PMC3876805 [dostęp 2022-10-24] (ang.).
  • Leah M. Hesse i inni, Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes, „Pharmacogenetics”, 14 (4), 2004, s. 225–238, DOI: 10.1097/00008571-200404000-00002, PMID: 15083067 [dostęp 2022-10-24] (ang.).
  • S.H. Preskorn, Should bupropion dosage be adjusted based upon therapeutic drug monitoring?, „Psychopharmacology Bulletin”, 27 (4), 1991, s. 637–643, PMID: 1813908 [dostęp 2022-10-24] (ang.).
  • R.F. Suckow i inni, Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 14 (6), 1986, s. 692–697, PMID: 2877828 [dostęp 2022-10-24] (ang.).
  • R.M. Welch, A.A. Lai, D.H. Schroeder, Pharmacological significance of the species differences in bupropion metabolism, „Xenobiotica; the Fate of Foreign Compounds in Biological Systems”, 17 (3), 1987, s. 287–298, DOI: 10.3109/00498258709043939, PMID: 3107223 [dostęp 2022-10-24] (ang.).
  • D. Weintraub, M.W. Linder, Amphetamine positive toxicology screen secondary to bupropion, „Depression and Anxiety”, 12 (1), 2000, s. 53–54, DOI: 10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4, PMID: 10999247 [dostęp 2022-10-24] (ang.).
  • A.L. Nixon i inni, Bupropion metabolites produce false-positive urine amphetamine results, „Clinical Chemistry”, 41 (6 Pt 1), 1995, s. 955–956, DOI: 10.1093/clinchem/41.6.955, PMID: 7768026 [dostęp 2022-10-24] (ang.).
  • publikacja w otwartym dostępie – możesz ją przeczytać Figure 3-4. Abuse potential of common psychiatric medications. W: Substance abuse treatment for persons with HIV/AIDS. Rockville: U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment, s. 83–84, seria: Treatment Improvement Protocol.

pubchem.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

nytimes.com

peoplespharmacy.com

psychiatrist.com

quackwatch.org

sigmaaldrich.com

tga.gov.au

ebs.tga.gov.au

uspto.gov

patft.uspto.gov

web.archive.org

webcitation.org

worldcat.org

  • Rozdział 3.3.3. → Bupropion, [w:] Grażyna Rajtar-Cynke, Farmakologia, wyd. 3, Warszawa: Wydawnictwo Lekarskie PZWL, 2015, ISBN 978-83-200-4869-8, OCLC 903361942.